for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up
Healthcare

BRIEF-Innovent And Eli Lilly Announce NMPA Acceptance Of Supplemental New Drug Application For Sintilimab

April 23 (Reuters) - Innovent Biologics Inc:

* INNOVENT AND ELI LILLY ANNOUNCE NMPA ACCEPTANCE OF A SUPPLEMENTAL NEW DRUG APPLICATION FOR SINTILIMAB IN COMBINATION WITH ALIMTA® (PEMETREXED) Source text for Eikon: Further company coverage:

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up